Referencia número: HY-16562

Irinotecan

(Synonyms: (+)-Irinotecan; CPT-11; VAL-413free base)

81 Cited Publications

Revisión del cliente

Based on 81 publication(s) in Google Scholar

Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.97%
No. CAS: 97682-44-5
Fòrmula: C₃₃H₃₈N₄O₆
Peso molecular:586.68

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Irinotecan Chemical Structure

No. CAS: 97682-44-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (81)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex^[1]^[5].

IC₅₀ & Target^[1]

Topoisomerase I

Ver todos los productos específicos de isoformas Topoisomerase :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	2.25 μM Compound: Irinotecan	Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
A2780	IC₅₀	3.8 μM Compound: Irinotecan	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 29150335]
A-375	IC₅₀	4 nM Compound: 6	Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
A-431	IC₅₀	4.1 μM Compound: Irinotecan	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay Antiproliferative activity against human A431 cells after 72 hrs by SRB assay	[PMID: 29150335]
A549	GI₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human A549 cells after 72 hrs by XTT assay Antiproliferative activity against human A549 cells after 72 hrs by XTT assay	[PMID: 19796956]
A549	GI₅₀	>10 μM Compound: Irinotecan	Growth inhibition of human A549 cells after 72 hrs by XTT assay Growth inhibition of human A549 cells after 72 hrs by XTT assay	[PMID: 22079254]
A549	GI₅₀	5 μM Compound: IRT	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
A549	IC₅₀	>10 μM Compound: 2; Irino	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
A549	IC₅₀	0.8 μM Compound: Irinotecan	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 26841168]
A549	IC₅₀	1557 nM Compound: Irinotecan	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
A549	IC₅₀	16.53 μM Compound: Ir	Cytotoxicity against human A549 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth by MTT assay	[PMID: 31972391]
A549	IC₅₀	1880.93 nM Compound: Irinotecan	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30115492]
A549	IC₅₀	19.71 μM Compound: Irinotecan	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
A549	IC₅₀	2 μM Compound: IR	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35964428]
A549	IC₅₀	20 μM Compound: IRT	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28351590]
A549	IC₅₀	20.1 μM Compound: IRT	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26226379]
A549	IC₅₀	26.69 μM Compound: 1c	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
A549	IC₅₀	32 nM Compound: Irinotecan	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	32 nM Compound: 4; CPT-11	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
A549	IC₅₀	4.61 μM Compound: 3, Camptosar	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20371183]
A549	IC₅₀	5237.6 nM Compound: Irinotecan	Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
A549	IC₅₀	6.13 μM Compound: CPT-11	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
A549	IC₅₀	6.4 μM Compound: IRT	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 20942490]
A549	IC₅₀	6.528 μM Compound: irinotecan	Antitumor activity against human A549 cells after 4 hrs by MTT assay Antitumor activity against human A549 cells after 4 hrs by MTT assay	[PMID: 18207748]
A549	IC₅₀	8.31 μM Compound: 2; CPT-11	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 28789891]
A549	IC₅₀	8300 nM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
A549	IC₅₀	8300 nM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 28927790]
A549	IC₅₀	9.48 μM Compound: 3	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23102893]
A549	IC₅₀	9.48 μM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 26994847]
A549	IC₅₀	9.5 μM Compound: 3	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 25003995]
A549	IC₅₀	9140 nM Compound: 5	Cytotoxicity against human A549 cells incubated for 48 hrs by by SpectraMax M5 microplate reader analysis Cytotoxicity against human A549 cells incubated for 48 hrs by by SpectraMax M5 microplate reader analysis	[PMID: 34175539]
BEAS-2B	IC₅₀	>10 μM Compound: 2; Irino	Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
Bone marrow cell	IC₅₀	1 nM Compound: 6	Cytotoxicity against mouse bone marrow cell by CFU-GM assay Cytotoxicity against mouse bone marrow cell by CFU-GM assay	[PMID: 21341674]
Bone marrow cell	IC₅₀	110 nM Compound: 6	Cytotoxicity against human bone marrow cell by CFU-GM assay Cytotoxicity against human bone marrow cell by CFU-GM assay	[PMID: 21341674]
CAPAN-1	IC₅₀	1.5 μM Compound: Irinotecan	Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells after 72 hrs by SRB assay	[PMID: 29150335]
CAPAN-1	IC₅₀	1121 nM Compound: Irinotecan	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
CCD-18Co	IC₅₀	18.5 μM Compound: Irinotecan	Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCD-841CoN	IC₅₀	13.2 μM Compound: Irinotecan	Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCD-841CoN	IC₅₀	90.25 μM Compound: 1c	Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human CCD-841CoN cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
COLO 205	IC₅₀	9.9 μM Compound: 1	Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay Cytotoxicity against human COLO 205 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
DG-75	IC₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay Antiproliferative activity against human DG75 cells after 72 hrs by MTT assay	[PMID: 29150335]
DLD-1	IC₅₀	13.17 μM Compound: Irino	Inhibition of human DLD-1 cell spheroids incubated for 7 days by luciferase based assay Inhibition of human DLD-1 cell spheroids incubated for 7 days by luciferase based assay	[PMID: 36780832]
DLD-1	IC₅₀	25.1 μM Compound: Irinotecan	Cytotoxicity against human DLD1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against human DLD1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	[PMID: 24583355]
DU-145	IC₅₀	0.96 μM Compound: 2; Irino	Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
DU-145	IC₅₀	2.8 μM Compound: Irinotecan	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	[PMID: 29150335]
DU-145	IC₅₀	200 nM Compound: 6	Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay Cytotoxicity against human DU145 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
DU-145	IC₅₀	9.3 μM Compound: 3	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 23102893]
DU-145	IC₅₀	9.3 μM Compound: 3	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay Cytotoxicity against human DU145 cells after 72 hrs by SRB assay	[PMID: 25003995]
H69AR	IC₅₀	250 nM Compound: 6	Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
HCT-116	GI₅₀	7.1 μM Compound: IRT	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
HCT-116	IC₅₀	>100 μM Compound: 2	Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
HCT-116	IC₅₀	0.6 μM Compound: Irinotecan	Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HCT-116	IC₅₀	0.91 μM Compound: CPT-11	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37312863]
HCT-116	IC₅₀	12.03 μM Compound: Irinotecan	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
HCT-116	IC₅₀	14.22 μM Compound: CPT-11	Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36639036]
HCT-116	IC₅₀	1633.47 nM Compound: Irinotecan	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 30115492]
HCT-116	IC₅₀	18.6 μM Compound: IRT	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26226379]
HCT-116	IC₅₀	2 μM Compound: Irinotecan	Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
HCT-116	IC₅₀	3.16 μM Compound: 2; Irino	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
HCT-116	IC₅₀	3.69 μM Compound: 1	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
HCT-116	IC₅₀	4.4 nM Compound: CPT-11	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
HCT-116	IC₅₀	498 nM Compound: Irinotecan	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
HCT-116	IC₅₀	498 nM Compound: 4; CPT-11	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
HCT-116	IC₅₀	6.3 μM Compound: IRT	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28351590]
HCT-116	IC₅₀	9.7 μM Compound: Irinotecan	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32736230]
HCT-15	IC₅₀	2.7 μM Compound: Irinotecan	Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HCT-15	IC₅₀	8.5 μM Compound: Irinotecan	Antiproliferative activity against human HCT15 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human HCT15 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
HEK293	IC₅₀	>100 μM Compound: 2	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32668379]
HEK293	IC₅₀	2.1 μM Compound: irinotecan	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	[PMID: 23241029]
HEK293	IC₅₀	2.7 μM Compound: irinotecan	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	20.8 μM Compound: irinotecan	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	7.9 μM Compound: irinotecan	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	7.9 μM Compound: irinotecan	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	74.6 μM Compound: irinotecan	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	78.6 μM Compound: irinotecan	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK-293T	IC₅₀	19.83 μM Compound: CPT-11	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth by MTT assay	[PMID: 36639036]
HeLa	GI₅₀	>1 μM Compound: irinotecan	Growth inhibition of HeLa cells after 4 days Growth inhibition of HeLa cells after 4 days	[PMID: 17418582]
HeLa	IC₅₀	122.5 nM Compound: 4; CPT-11	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
HeLa	IC₅₀	13.24 μM Compound: CPT-11	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HeLa	IC₅₀	32 nM Compound: Irinotecan	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30660827]
HeLa	IC₅₀	5.8 μM Compound: Irinotecan	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 29150335]
Hep 3B2	GI₅₀	4.73 μM Compound: Irinotecan	Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay	[PMID: 19796956]
Hep 3B2	GI₅₀	4.73 μM Compound: Irinotecan	Growth inhibition of human Hep3B cells after 72 hrs by XTT assay Growth inhibition of human Hep3B cells after 72 hrs by XTT assay	[PMID: 22079254]
HepG2	GI₅₀	5.94 μM Compound: Irinotecan	Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by XTT assay	[PMID: 19796956]
HepG2	GI₅₀	5.94 μM Compound: Irinotecan	Growth inhibition of human HepG2 cells after 72 hrs by XTT assay Growth inhibition of human HepG2 cells after 72 hrs by XTT assay	[PMID: 22079254]
HepG2	IC₅₀	>100 μM Compound: 2	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
HepG2	IC₅₀	0.9 μM Compound: Irinotecan	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 26841168]
HepG2	IC₅₀	10.8 μM Compound: CPT-11	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HepG2	IC₅₀	34.07 μM Compound: IR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35964428]
HepG2	IC₅₀	4 μM Compound: Irinotecan	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 29150335]
HepG2	IC₅₀	900 nM Compound: 4; CPT-11	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
HGC-27	IC₅₀	7.01 μM Compound: CPT-11	Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38554475]
HL-60	IC₅₀	32 nM Compound: Irinotecan	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	4.24 μM Compound: 1c	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HT-29	IC₅₀	1.9 μM Compound: Irinotecan	Antiproliferative activity against human HT-29 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human HT-29 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
HT-29	IC₅₀	220 nM Compound: 6	Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
HT-29	IC₅₀	3.55 μM Compound: Irinotecan	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs in hypoxia condition by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs in hypoxia condition by MTT assay	[PMID: 31675512]
HT-29	IC₅₀	3.96 μM Compound: Irinotecan	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31675512]
HT-29	IC₅₀	4.8 μM Compound: Irinotecan	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 29150335]
HT-29	IC₅₀	6.85 μM Compound: 1c	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
HT-29	IC₅₀	8.51 μM Compound: 1	Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay Cytotoxicity against human HT-29 cells incubated for 48 hrs by SRB assay	[PMID: 37413981]
HT-29	IC₅₀	82.75 μM Compound: Irinotecan	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	[PMID: 24583355]
HT-29	IC₅₀	9.5 μM Compound: Irinotecan	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32736230]
Huh-7	IC₅₀	>10 μM Compound: 2; Irino	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
IGROV-1	IC₅₀	30 nM Compound: 6	Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
JeKo-1	IC₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay Antiproliferative activity against human JeKo1 cells after 72 hrs by MTT assay	[PMID: 29150335]
K562	GI₅₀	1.9 μM Compound: Irinotecan	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 25420175]
KB	IC₅₀	6314.3 nM Compound: Irinotecan	Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
KB	IC₅₀	7.99 μM Compound: 2; CPT-11	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 28789891]
KB	IC₅₀	7990 nM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
KB	IC₅₀	7990 nM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 28927790]
KB	IC₅₀	9.8 μM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 25003995]
KB	IC₅₀	9.828 μM Compound: 3	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 26994847]
KB	IC₅₀	9.83 μM Compound: 3	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 23102893]
KB 3-1	IC₅₀	0.68 μM Compound: Irinotecan	Cytotoxicity against human KB3-1 cells by MTT method Cytotoxicity against human KB3-1 cells by MTT method	[PMID: 18771930]
KB-V1	IC₅₀	40 μM Compound: Irinotecan	Cytotoxicity against human KBV1 cells by MTT method Cytotoxicity against human KBV1 cells by MTT method	[PMID: 18771930]
KM-H2	IC₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay Antiproliferative activity against human KM-H2 cells after 72 hrs by MTT assay	[PMID: 29150335]
L02	IC₅₀	1305 nM Compound: Irinotecan	Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
L02	IC₅₀	22.22 μM Compound: CPT-11	Cytotoxicity against human L02 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36639036]
L1210	IC₅₀	1200 nM Compound: 4; CPT-11	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
L1210	IC₅₀	1200 nM Compound: 43	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
L-428	IC₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human L428 cells after 72 hrs by MTT assay Antiproliferative activity against human L428 cells after 72 hrs by MTT assay	[PMID: 29150335]
LNCaP	IC₅₀	9 nM Compound: 6	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 21341674]
LoVo	IC₅₀	4.99 μM Compound: 3, Camptosar	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 20371183]
LoVo	IC₅₀	8.8 μM Compound: IRT	Cytotoxicity against human LoVo cells after 3 days by MTT assay Cytotoxicity against human LoVo cells after 3 days by MTT assay	[PMID: 20942490]
LoVo	IC₅₀	9.015 μM Compound: irinotecan	Antitumor activity against human LOVO cells after 4 hrs by MTT assay Antitumor activity against human LOVO cells after 4 hrs by MTT assay	[PMID: 18207748]
LS-1034	IC₅₀	4.09 μM Compound: Irino	Inhibition of human LS1034 cell spheroids incubated for 7 days by luciferase based assay Inhibition of human LS1034 cell spheroids incubated for 7 days by luciferase based assay	[PMID: 36780832]
LS174T	IC₅₀	0.7 μM Compound: Irinotecan	Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
LS174T	IC₅₀	1.16 μM Compound: irinotecan	Cytotoxicity against human LS174T cells after 96 hrs by MTT assay Cytotoxicity against human LS174T cells after 96 hrs by MTT assay	[PMID: 18513976]
Malme-3M	IC₅₀	200 nM Compound: 6	Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay Cytotoxicity against human MALME-3M cells after 72 hrs by alamar blue assay	[PMID: 21341674]
MCF7	GI₅₀	>1 μM Compound: irinotecan	Growth inhibition of adriamycin-resistant MCF7 cells after 4 days Growth inhibition of adriamycin-resistant MCF7 cells after 4 days	[PMID: 17418582]
MCF7	GI₅₀	>1 μM Compound: irinotecan	Growth inhibition of MCF7 cells after 4 days Growth inhibition of MCF7 cells after 4 days	[PMID: 17418582]
MCF7	GI₅₀	>10 μM Compound: Irinotecan	Growth inhibition of human MCF7 cells after 72 hrs by XTT assay Growth inhibition of human MCF7 cells after 72 hrs by XTT assay	[PMID: 22079254]
MCF7	IC₅₀	0.16 μM Compound: Irinotecan	Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 50 nM AZD0156 by SRB assay Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.21 μM Compound: Irinotecan	Cytotoxicity against human MCF7 cells assessed as combination index measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Cytotoxicity against human MCF7 cells assessed as combination index measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	0.5 μM Compound: Irinotecan	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 26841168]
MCF7	IC₅₀	0.8 μM Compound: CPT11	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 33915258]
MCF7	IC₅₀	0.8 μM Compound: Irinotecan	Cytotoxicity against human MCF7 cells incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 24 hrs by MTT assay	[PMID: 31891260]
MCF7	IC₅₀	0.9 μM Compound: Irinotecan	Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human MCF7 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
MCF7	IC₅₀	0.91 μM Compound: Iri	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 37438997]
MCF7	IC₅₀	1.68 μM Compound: Irinotecan	Cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	1.88 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay Antagonistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	1.98 μM Compound: Irinotecan	Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU60019 by SRB assay Synergistic cytotoxicity against human MCF7 cells measured after 6 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	11.32 μM Compound: 2; CPT-11	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28789891]
MCF7	IC₅₀	11300 nM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MCF7	IC₅₀	11300 nM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28927790]
MCF7	IC₅₀	12.25 μM Compound: Ir	Cytotoxicity against human MCF-7 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human MCF-7 cells assessed as reduction in cell growth by MTT assay	[PMID: 31972391]
MCF7	IC₅₀	14.1 μM Compound: 1c	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs	[PMID: 34048881]
MCF7	IC₅₀	17.403 μM Compound: irinotecan	Antitumor activity against human MCF7 cells after 4 hrs by MTT assay Antitumor activity against human MCF7 cells after 4 hrs by MTT assay	[PMID: 18207748]
MCF7	IC₅₀	2.42 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells in presence of 30 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay Antagonistic cytotoxicity against human MCF7 cells in presence of 30 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 6 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	26.33 μM Compound: Irinotecan	Synergistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 2 days by SRB assay Synergistic cytotoxicity against human MCF7 cells in presence of 10 uM 3-Chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide measured after 2 days by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	38.1 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU55933 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	38.1 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU60019 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	39.2 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 50 nM AZD0156 by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	4.59 μM Compound: 2; Irino	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
MCF7	IC₅₀	42.4 μM Compound: Irinotecan	Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Antagonistic cytotoxicity against human MCF7 cells measured after 2 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
MCF7	IC₅₀	500 nM Compound: 4; CPT-11	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured for 24 hrs by SRB assay	[PMID: 38421819]
MDA-MB-231	GI₅₀	9.17 μM Compound: Irinotecan	Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 22079254]
MDA-MB-231	IC₅₀	>10 μM Compound: 2; Irino	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
MDA-MB-231	IC₅₀	14282 nM Compound: Irinotecan	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31881457]
MDA-MB-231	IC₅₀	15.56 μM Compound: 2; CPT-11	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28789891]
MDA-MB-231	IC₅₀	15600 nM Compound: 2	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MDA-MB-231	IC₅₀	15600 nM Compound: 2	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28927790]
MDA-MB-435	GI₅₀	12.2 μM Compound: IRT	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
MDA-MB-435	IC₅₀	1.14 μM Compound: 3, Camptosar	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20371183]
MDA-MB-435	IC₅₀	17 μM Compound: IRT	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 20942490]
MDA-MB-435	IC₅₀	6.3 μM Compound: IRT	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 26226379]
MDCK-II	IC₅₀	4.3 μM Compound: irinotecan	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	[PMID: 23241029]
MES-SA	IC₅₀	10 nM Compound: 6	Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay	[PMID: 21341674]
MES-SA/Dx5	IC₅₀	22 nM Compound: 6	Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
MG-63	IC₅₀	18.09 μM Compound: Ir	Cytotoxicity against human MG-63 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human MG-63 cells assessed as reduction in cell growth by MTT assay	[PMID: 31972391]
MIA PaCa-2	IC₅₀	1329 nM Compound: Irinotecan	Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
Mononuclear cell line	IC₅₀	25.4 μM Compound: Irinotecan	Cytotoxicity against patient-derived human mononuclear cells assessed as cell growth inhibition incubated for 72 hrs by FMCA assay Cytotoxicity against patient-derived human mononuclear cells assessed as cell growth inhibition incubated for 72 hrs by FMCA assay	[PMID: 36018000]
MRC5	GI₅₀	77.53 μM Compound: Irinotecan	Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 19796956]
NB-4	IC₅₀	1 μM Compound: Irinotecan	Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay Antiproliferative activity against human NB4 cells after 72 hrs by MTT assay	[PMID: 29150335]
NCI-H1299	GI₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay Antiproliferative activity against human H1299 cells after 72 hrs by XTT assay	[PMID: 19796956]
NCI-H1299	GI₅₀	>10 μM Compound: Irinotecan	Growth inhibition of human H1299 cells after 72 hrs by XTT assay Growth inhibition of human H1299 cells after 72 hrs by XTT assay	[PMID: 22079254]
NCI-H1299	IC₅₀	0.22 μM Compound: Irinotecan	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 6 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	0.27 μM Compound: Irinotecan	Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 6 days by SRB assay Synergistic cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	1.67 μM Compound: Irinotecan	Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 6 days by SRB assay Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	1.83 μM Compound: Irinotecan	Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 6 days by SRB assay Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 6 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	11.12 μM Compound: Irinotecan	Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 2 days by SRB assay Cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM 2(((2-(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	13.13 μM Compound: Irinotecan	Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 2 days by SRB assay Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU55933 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	15.22 μM Compound: Irinotecan	Antagonistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 2 days by SRB assay Antagonistic cytotoxicity against human NCI-H1299 cells measured in presence of 50 nM AZD0156 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1299	IC₅₀	9.83 μM Compound: Irinotecan	Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 2 days by SRB assay Additive cytotoxicity against human NCI-H1299 cells measured in presence of 5 uM KU60019 after 2 days by SRB assay	[PMID: 35231830]
NCI-H1417	IC₅₀	9.79 μM Compound: Irinotecan	Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H146	IC₅₀	11.51 μM Compound: Irinotecan	Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H1650	IC₅₀	39.67 μM Compound: Irinotecan	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H1650	IC₅₀	6.8 μM Compound: 2; Irino	Antiproliferative activity against human NCI-H1650 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H1650 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H1975	IC₅₀	21.49 μM Compound: Irinotecan	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H1975	IC₅₀	3.41 μM Compound: 2; Irino	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H211	IC₅₀	2.81 μM Compound: Irinotecan	Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H2170	IC₅₀	18.81 μM Compound: Irinotecan	Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H2228	IC₅₀	3.43 μM Compound: 2; Irino	Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H226	IC₅₀	4.25 μM Compound: Irinotecan	Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H446	IC₅₀	0.01 nM Compound: 3	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	0.13 nM Compound: 3	Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	0.15 nM Compound: 3	Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	0.78 μM Compound: 2; Irino	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
NCI-H460	IC₅₀	15 nM Compound: 6	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
NCI-H460	IC₅₀	2.4 μM Compound: Irinotecan	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 29150335]
NCI-H460	IC₅₀	27 nM Compound: 6	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA	[PMID: 21341674]
NCI-H460	IC₅₀	5.15 μM Compound: Irinotecan	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H520	IC₅₀	36.16 μM Compound: Irinotecan	Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H526	IC₅₀	0.49 μM Compound: Irinotecan	Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
NCI-H69	IC₅₀	22 nM Compound: 6	Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
NCI-H82	IC₅₀	2.26 μM Compound: Irinotecan	Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay	[PMID: 34459195]
OCI-Ly3	IC₅₀	>10 μM Compound: Irinotecan	Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-LY3 cells after 72 hrs by MTT assay	[PMID: 29150335]
Ovarian cancer cell line	IC₅₀	75.3 μM Compound: Irinotecan	Anticancer activity against patient-derived human Ovarian tumor cells assessed as tumor growth inhibition incubated for 72 hrs by FMCA assay Anticancer activity against patient-derived human Ovarian tumor cells assessed as tumor growth inhibition incubated for 72 hrs by FMCA assay	[PMID: 36018000]
PANC-1	IC₅₀	11 μM Compound: CPT-11	Cytotoxicity against human PANC-1 cells assessed as cell viability incubated for 14 days by crystal violet-based clonogenic assay Cytotoxicity against human PANC-1 cells assessed as cell viability incubated for 14 days by crystal violet-based clonogenic assay	[PMID: 38265364]
PC-3	IC₅₀	0.8 μM Compound: Irinotecan	Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human PC3 cells assessed as cellular DNA content after 72 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
PC-3	IC₅₀	3.67 μM Compound: 2; Irino	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
PC-3	IC₅₀	4 nM Compound: 6	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
PC-9	IC₅₀	3.84 μM Compound: 2; Irino	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT based ELISA	[PMID: 39106476]
RKO	IC₅₀	0.7 μM Compound: Irinotecan	Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
RKO	IC₅₀	6.2 μM Compound: Irinotecan	Antiproliferative activity against human RKO cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human RKO cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
RPMI 8402	IC₅₀	0.57 μM Compound: CPT-11(irinotecan)	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment	[PMID: 12747798]
SK-MEL-2	IC₅₀	100 nM Compound: 6	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
SK-OV-3	IC₅₀	13.63 μM Compound: Ir	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell growth by MTT assay	[PMID: 31972391]
SW1990	IC₅₀	>100 μM Compound: 2	Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
SW480	IC₅₀	<0.12 μM Compound: Irinotecan	Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU60019 by SRB assay Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	<0.12 μM Compound: Irinotecan	Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 50 nM AZD0156 by SRB assay Synergistic cytotoxicity against human SW480 cells measured after 9 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	0.07 μM Compound: Irinotecan	Cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
SW480	IC₅₀	0.6 μM Compound: Irinotecan	Additive cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU55933 by SRB assay Additive cytotoxicity against human SW480 cells measured after 9 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	1.4 μM Compound: CPT11	Cytotoxicity against human SW480 cells by MTT assay Cytotoxicity against human SW480 cells by MTT assay	[PMID: 33915258]
SW480	IC₅₀	1.4 μM Compound: Irinotecan	Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 26841168]
SW480	IC₅₀	1.4 μM Compound: Irinotecan	Cytotoxicity against human SW480 cells incubated for 24 hrs by MTT assay Cytotoxicity against human SW480 cells incubated for 24 hrs by MTT assay	[PMID: 31891260]
SW480	IC₅₀	11.17 μM Compound: CPT-11	Anticancer activity against human SW480 cells assessed as inhibition of cell growth by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36639036]
SW480	IC₅₀	12.3 μM Compound: Irinotecan	Antiproliferative activity against human SW480 cells after 24 to 72 hrs by SRB assay Antiproliferative activity against human SW480 cells after 24 to 72 hrs by SRB assay	[PMID: 26595875]
SW480	IC₅₀	12.4 μM Compound: Irinotecan	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM 2(((24(2,4-dichlorobenzyl)oxy)naphthalen-1-yl)methyl)amino)ethan-1-ol by SRB assay	[PMID: 35231830]
SW480	IC₅₀	12.4 μM Compound: Irinotecan	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 50 nM AZD0156 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 50 nM AZD0156 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	15.4 μM Compound: Irinotecan	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU60019 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU60019 by SRB assay	[PMID: 35231830]
SW480	IC₅₀	3.8 μM Compound: Irinotecan	Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
SW480	IC₅₀	7.2 μM Compound: Irinotecan	Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU55933 by SRB assay Antagonistic cytotoxicity against human SW480 cells measured after 3 days in presence of 5 uM KU55933 by SRB assay	[PMID: 35231830]
SW-620	IC₅₀	0.14 μM Compound: CPT-11	Anticancer activity against human SW620 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Anticancer activity against human SW620 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37312863]
SW-620	IC₅₀	0.23 μM Compound: Iri	Inhibition of colony formation in human SW620 cells measured after 1 week by crystal violet staining based chemiluminescence assay Inhibition of colony formation in human SW620 cells measured after 1 week by crystal violet staining based chemiluminescence assay	[PMID: 37438997]
SW-620	IC₅₀	0.98 μM Compound: Iri	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 37438997]
SW-620	IC₅₀	5.1 nM Compound: CPT-11	Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
T84	IC₅₀	1.2 μM Compound: Irinotecan	Antiproliferative activity against human T84 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay Antiproliferative activity against human T84 cells assessed as cellular DNA content after 96 hrs by CyQUANT NF fluorescence assay	[PMID: 26731300]
T84	IC₅₀	6.9 nM Compound: CPT-11	Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 33221063]
U2932	IC₅₀	4.4 μM Compound: Irinotecan	Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay Antiproliferative activity against human U2932 cells after 72 hrs by MTT assay	[PMID: 29150335]
U2OS	IC₅₀	14.21 μM Compound: Ir	Cytotoxicity against human U2OS cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell growth by MTT assay	[PMID: 31972391]
U-87MG ATCC	IC₅₀	>250 μM Compound: Irinotecan	Cytotoxicity against human U87 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human U87 cells assessed as growth inhibition after 72 hrs by SRB assay	10.1039/C4MD00264D
WiDr	IC₅₀	13.9 μM Compound: Irinotecan	Anticancer activity against human WiDr cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Anticancer activity against human WiDr cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 34425478]
ZR-75-30	IC₅₀	18 μM Compound: IRT	Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay	[PMID: 28351590]

In Vitro

Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC₅₀s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells^[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC₅₀ of 1.3 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p^[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 97682-44-5
Appearance Solid
Peso molecular 586.68
Fòrmula C₃₃H₃₈N₄O₆
Color White to yellow
SMILES

O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3
Synonyms

(+)-Irinotecan; CPT-11; VAL-413free base
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (81)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCWBCell Imaging/StainingIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. [Abstract]

2021 May 28;6(1):188. PMID: 34045438

Irinotecan purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 May 28;6(1):188. [Abstract]

Irinotecan (10 μM; 0–4 days). Cystine promoted colon cancer resistance to oxaliplatin and irinotecan (CPT-11) in vitro.
Cancer Cell

Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]

2026 Mar 9;44(3):658-675.e12. PMID: 41687606
Cancer Cell

Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches. [Abstract]

2025 Sep 25:S1535-6108(25)00393-9. PMID: 41005303
Cancer Cell

Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. [Abstract]

2025 Jul 14;43(7):1296-1312.e7. PMID: 40513578
Cell

Sublethal cytochrome c release generates drug-tolerant persister cells. [Abstract]

2022 Sep 1;185(18):3356-3374.e22. PMID: 36055199
Mol Cancer

Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation. [Abstract]

2024 Apr 4;23(1):70. PMID: 38576002
Adv Mater

Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy. [Abstract]

2026 Mar 15:e22617. PMID: 41834342
Gastroenterology

AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]

2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Nat Commun

2026 May 28.
Acta Pharm Sin B

Eubacterium coprostanoligenes alleviates chemotherapy-induced intestinal mucositis by enhancing intestinal mucus barrier. [Abstract]

2024 Apr;14(4):1677-1692. PMID: 38572095

Irinotecan purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]

Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Tumor volume in the control, CPT/5FU and E. copr groups were recorded daily.

Irinotecan purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]

Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Expression of PCNA was measured by IHC and quantified by ImageJ in the tumor sections. Scale bar: 100 mm.
Adv Sci (Weinh)

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer. [Abstract]

2025 May 8:e2500271. PMID: 40344511
Adv Sci (Weinh)

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. [Abstract]

2025 Jan 31:e2408845. PMID: 39888307
Theranostics

A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. [Abstract]

2019 May 31;9(13):3732-3753. PMID: 31281510
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
Cell Discov

Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. [Abstract]

2022 Sep 14;8(1):92. PMID: 36104333
Redox Biol

Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. [Abstract]

2024 May 23:73:103207. PMID: 38805974
Genome Med

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. [Abstract]

2016 Oct 31;8(1):116. PMID: 27799065
EBioMedicine

A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. [Abstract]

2023 Jun:92:104594. PMID: 37167784
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. [Abstract]

2024 Mar 19;5(3):101468. PMID: 38508144
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
Pharmacol Res

Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. [Abstract]

2021 Jan;163:105232. PMID: 33027716
Clin Cancer Res

Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair. [Abstract]

2023 Nov 14;29(22):4644-4659. PMID: 37725585
Cancer Lett

HOXC8-activated TRIM22/NF-κB pathway promotes stemness in colorectal cancer. [Abstract]

2026 Jan 28:638:218156. PMID: 41265630
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556
Acta Biomater

MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway. [Abstract]

2025 Aug 12:S1742-7061(25)00602-6. PMID: 40812610
Cell Death Dis

Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity. [Abstract]

2025 Apr 5;16(1):253. PMID: 40185729
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]

2025 Jan 18;16(1):28. PMID: 39827156
Cell Death Dis

Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response. [Abstract]

2024 Jun 15;15(6):417. PMID: 38879509
Cell Death Dis

Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy. [Abstract]

2019 Nov 25;10(12):887. PMID: 31767864
Apoptosis

Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. [Abstract]

2019 Apr;24(3-4):312-325. PMID: 30710195
Apoptosis

Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. [Abstract]

2016 Feb;21(2):130-42. PMID: 26531131

Irinotecan purchased from MedChemExpress. Usage Cited in: Apoptosis. 2016 Feb;21(2):130-42. [Abstract]

(a) CPT-11 induces cell cycle arrest and apoptosis in RAW 264.7macrophages. a.Western blot analysis of cleaved caspase-3 and PARP levels. (b) CPT-11 induced cell cycle arrest and apoptosis in mouse peritoneal macrophages. Western blot analysis of cleaved caspase-3 and PARP levels in peritoneal macrophages isolated from vehicleand CPT-11-administered mice. (c) Caspase-3 inhibitor z-DEVD-fmk (ZD) attenuates CPT-11-induced loss of GATA6⁺ peritoneal macrophages in mice. Western blot analy
NPJ Precis Oncol

Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study. [Abstract]

2025 Jul 1;9(1):207. PMID: 40595395
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073
Biomed Pharmacother

Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. [Abstract]

2020 Aug;128:110262. PMID: 32447214
Oncogene

Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability. [Abstract]

2026 Jun 15. PMID: 42298179
Oncogene

CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis. [Abstract]

2025 Jun;44(22):1678-1693. PMID: 40089640

Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

Analysis of drug sensitivity in various SW480 and HCT116 cell lines after 48 h of treatment with with Irinotecan (1 μmol/L).

Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

Irinotecan (1 μmol/L, 48 h). Western blotting assays on caspase-3 and cleaved caspase-3 in SW480-Con/CBX3 cells following chemotherapy.

Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Immunohistochemical staining of tumor tissues with antibodies against Ki67, NRF2, and GPX2 (low-power view 100×, high-power view 400×, scale bar = 50 μm).

Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Tumors were measured every two days, and the tumor volumes were calculated. The tumors were excised and weighed 34 days after injection, and representative images of tumors were displayed (bar = 10 mm).

Irinotecan purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]

SW480-Con/CBX3 cells were treated with Irinotecan (1 μmol/L) for 8 h and stained with C11 BODIPY (oxidized lipid was stained green) and then detected by both flow cytometry and confocal microscopy. ERTracker Blue-White was used to detect the location of lipid oxidation by confocal microscopy (high-power view 400×, scale bar = 50 μm) (N = 3).
PLoS Biol

Camptothecin effectively treats obesity in mice through GDF15 induction. [Abstract]

2022 Feb 24;20(2):e3001517. PMID: 35202387
Cell Biosci

Modulation of cell cycle increases CRISPR-mediated homology-directed DNA repair. [Abstract]

2023 Nov 25;13(1):215. PMID: 38007480
Front Immunol

Prolonged Deleterious Influences of Chemotherapeutic Agent CPT-11 on Resident Peritoneal Macrophages and B1 Cells. [Abstract]

2018 Jan 5:8:1919. PMID: 29354128
Biochem Pharmacol

Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice. [Abstract]

2023 Oct:216:115752. PMID: 37634598
Mol Cancer Ther

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. [Abstract]

2021 Dec;20(12):2483-2494. PMID: 34711645
Mol Ther Oncol

A KRASG12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [Abstract]

2025 Nov 22;33(4):201098. PMID: 41438133
Cells

Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer. [Abstract]

2026 Feb 28;15(5):430. PMID: 41827864
Int J Pharm

Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel. [Abstract]

2020 Jun 30:584:119337. PMID: 32371002
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Food Hydrocoll Health

2025 Jun.
Life Sci

The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. [Abstract]

2019 Aug 15:231:116529. PMID: 31173781
Precis Clin Med

Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]

2026 Mar 14;9(2):pbag009. PMID: 41978696
PLoS Pathog

BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. [Abstract]

2020 Mar 24;16(3):e1008429. PMID: 32208449
Eur J Pharmacol

Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer. [Abstract]

2023 Jun 15:949:175718. PMID: 37054937
Mol Cancer Res

Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. [Abstract]

2020 Mar;18(3):414-423. PMID: 31932471
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancers (Basel)

In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]

2023 Sep 6;15(18):4442. PMID: 37760412
Lung Cancer

TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. [Abstract]

2023 Apr:178:237-246. PMID: 36907051
Eur J Pharm Biopharm

Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. [Abstract]

2022 Feb:171:39-49. PMID: 34998911
J Mol Med (Berl)

The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis. [Abstract]

2026 Apr 23;104(1):68. PMID: 42020785
Biochim Biophys Acta Mol Basis Dis

Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α. [Abstract]

2024 Aug 16:167471. PMID: 39154793
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy. [Abstract]

2024 Nov 26;14(1):29265. PMID: 39587206
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Heliyon

The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway. [Abstract]

2023 Apr 27;9(5):e15805. PMID: 37251857
J Pharm Pharmacol

Indolocarbazole alkaloid Loonamycin A inhibits triple-negative breast cancer cell stemness and Notch signalling. [Abstract]

2023 Apr 7;75(4):523-532. PMID: 36861187

Irinotecan purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Apr 7;75(4):523-532. [Abstract]

Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.
Mol Biol Cell

Mitotic DNA damage promotes chromokinesin-mediated missegregation of polar chromosomes in cancer cells. [Abstract]

2023 May 1;34(5):ar47. PMID: 36989031
Gene

Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells. [Abstract]

2019 Mar 10:688:1-6. PMID: 30415007
BMC Med Genomics

The role of TEAD4 gene in the Hippo signaling pathway in triple-negative breast cancer and targeted therapy strategies. [Abstract]

2025 Oct 30;18(1):172. PMID: 41168787
University of North Carolina at Chapel Hill

2026.
bioRxiv

Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]

2026 May 23:2026.05.20.726695. PMID: 42239384
Res Sq

2026 Jan 9.
SSRN

2026 Jan 26.
Res Sq

Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax. [Abstract]

2025 Nov 19:rs.3.rs-7682325. PMID: 41333384
bioRxiv

CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma. [Abstract]

2025 Sep 26:2025.09.24.677357. PMID: 41040216
bioRxiv

2025 Sep 21.
bioRxiv

2025 Sep 17.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
Ruperto Carola University Heidelberg

2022 Mcr 16.
Patent

US20210009719A1.
bioRxiv

2019 Dec.

Solvente y solubilidad

In Vitro:

DMSO : 23.33 mg/mL (39.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7045 mL

8.5225 mL

17.0451 mL

5 mM

0.3409 mL

1.7045 mL

3.4090 mL

10 mM

0.1705 mL

0.8523 mL

1.7045 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/1% Tween-80 in Saline water

Solubility: 10 mg/mL (17.05 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[2]

Exponentially growing cells are seeded in 20 cm² dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC₅₀ values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (280 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [Content Brief]

[2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [Content Brief]

[3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. [Content Brief]

[4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. [Content Brief]

[5]. Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42. [Content Brief]

[6]. Goldwirt L, et al. Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol. 2014 Jul;74(1):185-93. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7045 mL	8.5225 mL	17.0451 mL	42.6127 mL
	5 mM	0.3409 mL	1.7045 mL	3.4090 mL	8.5225 mL
	10 mM	0.1705 mL	0.8523 mL	1.7045 mL	4.2613 mL
	15 mM	0.1136 mL	0.5682 mL	1.1363 mL	2.8408 mL
	20 mM	0.0852 mL	0.4261 mL	0.8523 mL	2.1306 mL
	25 mM	0.0682 mL	0.3409 mL	0.6818 mL	1.7045 mL
	30 mM	0.0568 mL	0.2841 mL	0.5682 mL	1.4204 mL

Keywords

Irinotecan

81 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Irinotecan

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Irinotecan

Ver todos los productos específicos de isoformas Topoisomerase

Actividad biológica

Chemical Information

Publications (81)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Irinotecan Related Classifications

HY-16562 Related Classifications